GH Research PLC's stock price soared 5.19% during pre-market trading on Monday, following significant developments in its clinical pipeline and financial strategy.

The movement appears to be driven by the company's recent publication of positive Phase 2b data for its lead asset GH001 in the prestigious JAMA Psychiatry journal, along with the completion of key Phase 1 studies. These clinical milestones advance the treatment-resistant depression program toward Phase 3 initiation and future regulatory interactions, strengthening the investment narrative around this single late-stage asset.

Additionally, GH Research has enhanced its financial flexibility by adding a US$200 million at-the-market facility and a US$400 million universal shelf registration. These new financing tools are designed to support the company's late-stage development plans, although they also introduce considerations around potential future dilution as the company continues to fund its operations and clinical trials.